Recombinant Plasma Protein Therapeutics Market 2018-2026 | Size, Share, Trends, Opportunities and Forecast | Credence Research

Recombinant plasma protein therapeutics market is set to grow from US$ 7,788.9 Mn in 2017 to US$ 15,910.5 Mn by 2026 expanding at a CAGR of 8.3% from 2018 to 2026

The latest market report published by Credence Research, Inc. “Global Recombinant Plasma Protein Therapeutics Market - Growth, Future Prospects, Competitive Analysis, 2018 - 2026,” the global recombinant plasma protein therapeutics market is set to grow from US$ 7,788.9 Mn in 2017 to US$ 15,910.5 Mn by 2026 expanding at a CAGR of 8.3% from 2018 to 2026.

Market Insights

Blood clotting disorders has an occurrence rate of 1 in 1,000 people worldwide with many patients remaining undiagnosed during their lifetime. Human plasma derived proteins are being completely replaced by recombinant coagulation factors owing to lack of transmission of blood borne infectious disease. High titer ratio of protein production by employing recombinant technology provides positive support to the recombinant plasma protein therapeutics market growth.

Get Sample Research Report at https://www.credenceresearch.com/sample-request/59670

Recombinant coagulation factor VIII is leading the drug class segment for recombinant plasma protein therapeutics market. It has completely replaced human blood plasma derived proteins and desmopressin in treating severe and mild form of hemophilia A. Recombinant coagulation factor IX will gain momentum in the near future owing to recent approval of Rebinyn (Novo Nordisk) for treating long term hemophilia B.

Hemophilia A is currently dominating the indication segment for recombinant plasma protein therapeutics market. High prevalence rate and occurrence of severe form in 70% diagnosed patients drives its market growth. Von Willebrand disease will register outstanding growth in the near future owing to USFDA approval of VONVENDI (Shire, Plc.) in April 2018.

Chinese hamster ovary will be the leading and fastest growing cell line segment for recombinant plasma protein therapeutics market for the entire forecast period. Its inherent features such as ability to adapt growing conditions in serum free suspension, powerful gene amplification and capacity for post translational modification in comparison to other cell lines utilized in recombinant protein synthesis.

Request for customization research report @ https://www.credenceresearch.com/request-for-customization/59670

North America with a market share of 40% is the leading regional segment for recombinant plasma protein therapeutics market. The major factors influencing its market growth are rising prevalence of hemophilia A and existence of comprehensive network of federally funded hemophilia treatment centers. Europe with a share of 30% is in the second position owing to domicile of key players such as CSL Behring, Novo Nordisk and Bayer AG. Asia Pacific represents 20% share and will eventually grow in the coming years on account of increased adoption of recombinant biotechnology for production of coagulation factors.

Biotechnology companies manufacturing recombinant plasma proteins are Aptevo Therapeutics, Bayer AG, Bioverativ Therapeutics, Inc., CSL Behring, Novo Nordisk A/S, Octapharma, Plc., Pfizer, Inc., Pharming Group NV, Shire, Plc. and Viropharma Biologics, Inc.

Key Market Movements:

Increasing diagnosis of blood clotting disorders such as hemophilia A, hemophilia B and Von Willebrand disease
Existence of comprehensive network of federally or centrally funded hemophilia treatment centers in the developed nations such as North America and Europe
Recent approval of recombinant coagulation factors by the USFDA has completely replaced human derived plasma proteins to treat blood clotting disorders

Browse the full report Recombinant Plasma Protein Therapeutics Market - Growth, Future Prospects, Competitive Analysis, 2018 – 2026 at https://www.credenceresearch.com/report/recombinant-plasma-protein-therapeutics-market

TOC:
Chapter 1. Preface
...............
Chapter 2. Executive Summary
...............
Chapter 3. Recombinant Plasma Protein Therapeutics Market: Dynamics and Future Outlook
...............
Chapter 4. Global Recombinant Plasma Protein Therapeutics Market, by Drug Class
4.1. Overview
4.2. Recombinant Factor VIII
4.3. Recombinant Factor IX

Chapter 5. Global Recombinant Plasma Protein Therapeutics Market, by Cell Line
5.1. Overview
5.2. Chinese Hamster Ovary
5.3. Baby Hamster Kidney
5.4. Human Embryonic Kidney
5.5. Others

Chapter 6. Global Recombinant Plasma Protein Therapeutics Market, by Indication
6.1. Overview
6.2. Hemophilia A
6.3. Hemophilia B
6.4. Von Willebrand Disease
6.5. Others
...............
Chapter 7. Global Recombinant Plasma Protein Therapeutics Market, by Geography
7.1. Overview
7.2. North America Recombinant Plasma Protein Therapeutics Market Analysis, 2016 – 2026
7.2.1. North America Recombinant Plasma Protein Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
7.2.2. North America Recombinant Plasma Protein Therapeutics Market, by Cell Line, 2016 – 2026 (US$ Mn)
7.2.3. North America Recombinant Plasma Protein Therapeutics Market, by Indication, 2016 – 2026 (US$ Mn)
7.2.4. North America Recombinant Plasma Protein Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
7.2.4.1. U.S.
7.2.4.2. Canada
...............
Chapter 8. Company Profiles
8.1. Aptevo Therapeutics.
8.1.1. Business Description
8.1.2. Financial Information (Subject to data availability)
8.1.3. Product Portfolio
8.1.4. News Coverage
8.2. Bayer AG
8.3. Bioverativ Therapeutics, Inc.
8.4. CSL Behring
8.5. Novo Nordisk A/S
8.6. Octapharma, Plc.
8.7. Pfizer, Inc.
8.8. Pharming Group NV
8.9. Shire, Plc.
8.10. Viropharma Biologics, Inc.
..................toc continued

Browse the full report Recombinant Plasma Protein Therapeutics Market 2018 – 2026 at https://www.credenceresearch.com/report/recombinant-plasma-protein-therapeutics-market

About Us:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.

Related Reports:

Molecular Diagnostics Market By Product (Reagents And Kits, Instruments, Services And Software), By Technology, By Application - Growth, Share, Opportunities & Competitive Analysis 2017 - 2025

Rapid Microbiology Tests Market By Technology (Nucleic Acid Based Test, Antibody Based Test, Biochemical Test, Enzymatic Test, Flow Cytometry Methods, Polymerase Chain Reaction (PCR) Methods, Impedance Methods), By End User (Food And Beverages, Pharmaceutical, Environmental, Personal Care) - Growth, Share, Opportunities & Competitive Analysis 2016 - 2022

Medical Imaging Reagents Market By Class Type (Contrast Reagents, Optical Reagents, Nuclear Reagents), By Technology, By Application (Diagnostics, Drug Discovery And Development, Research And Development) - Growth, Share, Opportunities & Competitive Analysis 2015 - 2022

Contact Info:
Name: Chris Smith
Email: Send Email
Organization: Credence Research Inc
Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US
Phone: +18003618290
Website: https://www.credenceresearch.com

Release ID: 505141